Collapsed Cakes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Collapsed Cakes

Equipment and Processing Report

Untitled Document

Q: We have changed the brand of our stoppers for a product that we freeze-dry in vials. Since the change, we have observed a significant increase in rejects for collapsed cakes. Why are the cakes collapsing? What can we do to prevent this problem?

A: When selecting stoppers, we take great care to specify various details, such as the formulation of the rubber, the quality of its surface, and the surface treatment, out of concern for the stability of our product. One important specification, however, is sometimes overlooked. This specification is the surface area of the openings or windows in the stopper that result when the stopper is placed on the vial at the prestoppering stage. The window is the route by which water vapor exits the vial during sublimation and desorption; it restricts the passage of vapor.

When you changed the brand of stoppers, you may have reduced the surface area of the window inadvertently. Smaller windows provide greater restriction and could increase the pressure inside the vial, thus causing a consequent increase in sublimation-front temperature. If this temperature exceeds the collapse temperature, you will find an increased number of collapsed cakes. Examine the window geometries of your old and new brands of stoppers and evaluate whether they have equivalent surface areas.

—Robert Bullich, process development manager at TELSTAR

 

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Equipment and Processing Report,
Click here